SEC Company Response from ROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) (CIK 0001281895) (RCKT) — Apr 12, 2016
ROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) (CIK 0001281895)
Date: April 12, 2016 · CIK: 0001281895 · Accession: 0001193125-16-538750
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-210585
Letter
INOTEK PHARMACEUTICALS CORPORATION
91 Hartwell Avenue
Lexington, MA
April 12, 2016
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Inotek Pharmaceuticals Corporation
Registration Statement on Form S-3
File No. 333- 210585
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Inotek Pharmaceuticals Corporation (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-210585) (the “Registration Statement”), so that it may become effective at 9:00 a.m. Eastern Time on April 14, 2016, or as soon thereafter as practicable.
The Registrant hereby acknowledges that:
1. should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
2. the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
3. the Registrant may not assert staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
Inotek Pharmaceuticals Corporation
Show Raw Text
CORRESP 1 filename1.htm CORRESP INOTEK PHARMACEUTICALS CORPORATION 91 Hartwell Avenue Lexington, MA 02421 April 12, 2016 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Inotek Pharmaceuticals Corporation Registration Statement on Form S-3 File No. 333- 210585 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Inotek Pharmaceuticals Corporation (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-210585) (the “Registration Statement”), so that it may become effective at 9:00 a.m. Eastern Time on April 14, 2016, or as soon thereafter as practicable. The Registrant hereby acknowledges that: 1. should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; 2. the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and 3. the Registrant may not assert staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Very truly yours, Inotek Pharmaceuticals Corporation By: /s/ David P. Southwell Name: Title: David P. Southwell President and Chief Executive Officer Cc: Mitchell S. Bloom, Esq. (Goodwin Procter LLP) Edwin O’Connor, Esq. (Goodwin Procter LLP)